The overall findings imply that accompanying CP with RTX and anti-Nrf2 siRNA not only augments drug entry to the primary malignant cells in CLL but it also can increase the potential efficacy of CP on these cells by impeding Nrf2 expression. Here, NFE2L2 is linked to B-cell chronic lymphocytic leukemia.